The global cyclin dependent kinase market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Cyclin-dependent kinases (CDKs) are protein kinases that are categorized by requiring a separate subunit, a cyclin. They provide domains essential for enzymatic activity and plays an important role in the control of cell division. Additionally, they modulate transcription in response to several extra- and intracellular cues. The major factor driving the growth of the market is the increasing prevalence of cancer across the globe. 

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. Additionally, the most common cancers include breast cancer, lung and bronchus cancer, and leukemia, among others. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers include breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020. Hence, the rising prevalence of cancer is supporting the demand for cyclin dependent kinase to block uncontrolled cellular proliferation, which in turn, is driving the growth of the market. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Route of Administration

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Pfizer Inc., Eli Lilly and Company, and Novartis International AG, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Cyclin Dependent Kinase Market Report by Segment

By Type

• Specific inhibitors
• Non-Specific or Broad Range Inhibitors
• Multiple target inhibitors

By Route of administration

• Nasal
• Oral
• Intravenous
• Intramuscular

By Application

• Breast cancer
• Lymphoma
• Multiple Myeloma
• Ovarian cancer
• Others

Global Cyclin Dependent Kinase Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa